GAM Holding AG Has $741,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

GAM Holding AG reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 71.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,530 shares of the medical device company's stock after selling 23,609 shares during the quarter. GAM Holding AG's holdings in DexCom were worth $741,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Versant Capital Management Inc bought a new stake in DexCom in the fourth quarter worth about $25,000. Heck Capital Advisors LLC bought a new stake in DexCom in the fourth quarter worth about $38,000. MassMutual Private Wealth & Trust FSB raised its position in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock worth $65,000 after acquiring an additional 265 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new stake in DexCom in the third quarter worth about $57,000. Finally, Park Place Capital Corp raised its position in DexCom by 3,516.7% in the fourth quarter. Park Place Capital Corp now owns 868 shares of the medical device company's stock worth $68,000 after acquiring an additional 844 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares of the company's stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research report on Saturday, November 2nd. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Raymond James dropped their price target on DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company lifted their price target on DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Finally, Leerink Partners lowered their target price on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has a consensus rating of "Moderate Buy" and a consensus price target of $99.06.

DexCom Stock Down 0.6 %

Shares of DexCom stock traded down $0.56 during trading on Friday, hitting $88.78. 3,729,437 shares of the stock traded hands, compared to its average volume of 3,632,823. The stock has a market cap of $34.69 billion, a P/E ratio of 62.08, a PEG ratio of 2.31 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a fifty day moving average price of $83.26 and a two-hundred day moving average price of $75.94.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.